Project description DEENESFRITPL New way to fight chronic pain Chronic pain is pain that lasts a long time, even after an injury heals. It affects more than 20 % of the population causing problems in everyday life. Chronic pain is treated with a combination of several analgesic drugs administered according to each physician’s decision based on their own best experiences. This is often not effective and it could even cause harmful effects. The EU-funded QSPainRelief project will develop a platform to improve treatment and relieve chronic pain with an effective combination of drugs thanks to a mechanism of quantitative systems pharmacology based on mathematical modelling (in silico modelling). It will allow physicians to identify and test effective, personally targeted therapy through the smart combination of drugs for each patient case. Show the project objective Hide the project objective Objective Chronic pain is a complex disease suffered by about 20% of Europeans. Up to 60% of these patients do not experience adequate pain relief from currently available analgesic combinational therapies and/or suffer confounding adverse effects. Of the many conceivable combinations only a few have been studied in formal clinical trials. Thus, physicians have to rely on clinical experience when treating chronic pain patients. The vision of the QSPainRelief consortium is that alternative novel drug combinations with improved analgesic and reduced adverse effects can be identified and assessed by mechanism-based Quantitative Systems Pharmacology in silico modelling. This is far cheaper and less time-consuming than clinical trials. We will develop an in silico QSPainRelief platform which integrates recently developed 1) physiologically based pharmacokinetic model to quantitate and adequately predict drug pharmacokinetics in human CNS, 2) target-binding kinetic models; 3) cellular signalling models and 4) a proprietary neural circuit model to quantitate the drug effects on the activity of relevant brain neuronal networks, that also adequately predicts clinical outcome. This platform will include patient characteristics such as age, sex, disease status and genotypes, and will predict efficacy and tolerability of a wide range of analgesic and other centrally active drug combinations, and rank these. The best combinations will then be validated in a suitable animal model, in two clinical studies in healthy volunteers, as well as in real world clinical practice. Quantitative insights and confirmed effective combinational treatments will result in a game-changer by improving the management of pain in individuals and stratified sub-populations of chronic pain patients, and reduce the large burden on health-care providers greatly. It would also increase the understanding of chronic pain in general, and trigger the development of even better combination therapies in the future. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics Keywords Quantitative Systems Pharmacology Personalised medicine Chronic pain Drug combinations In-silico discovery Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.1. - Understanding health, wellbeing and disease Topic(s) SC1-BHC-02-2019 - Systems approaches for the discovery of combinatorial therapies for complex disorders Call for proposal H2020-SC1-BHC-2018-2020 See other projects for this call Sub call H2020-SC1-2019-Two-Stage-RTD Funding Scheme RIA - Research and Innovation action Coordinator UNIVERSITEIT LEIDEN Net EU contribution € 1 404 207,50 Address Rapenburg 70 2311 EZ Leiden Netherlands See on map Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,50 Participants (9) Sort alphabetically Sort by Net EU contribution Expand all Collapse all IN SILICO BIOSCIENCES, INC United States Net EU contribution € 1 095 875,00 Address 405 waltham street 02421 Lexington ma See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 PD-VALUE BV Netherlands Net EU contribution € 298 375,00 Address Baardgras 24 3994 NZ Houten See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region West-Nederland Utrecht Utrecht Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 CONCENTRIS RESEARCH MANAGEMENT GMBH Germany Net EU contribution € 530 000,00 Address Ludwigstr. 4 82256 Furstenfeldbruck See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Bayern Oberbayern Fürstenfeldbruck Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 UNIVERSITAT AUTONOMA DE BARCELONA Spain Net EU contribution € 340 875,00 Address Edif a campus de la uab bellaterra cerdanyola v 08193 Cerdanyola del valles See on map Region Este Cataluña Barcelona Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 UNIVERSIDAD POMPEU FABRA Spain Net EU contribution € 585 875,00 Address Placa de la merce, 10-12 08002 Barcelona See on map Region Este Cataluña Barcelona Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA Italy Net EU contribution € 390 875,00 Address Via zamboni 33 40126 Bologna See on map Region Nord-Est Emilia-Romagna Bologna Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 UNIVERSITE CATHOLIQUE DE LOUVAIN Belgium Net EU contribution € 848 320,00 Address Place de l universite 1 1348 Louvain la neuve See on map Region Région wallonne Prov. Brabant Wallon Arr. Nivelles Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 STICHTING CENTRE FOR HUMAN DRUG RESEARCH Netherlands Net EU contribution € 677 636,25 Address Zernikedreef 8 2333 CL Leiden See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 CLINIQUES UNIVERSITAIRES SAINT-LUC ASBL Belgium Net EU contribution € 67 500,00 Address Avenue hippocrate 10 1200 Bruxelles / brussel See on map Region Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad Activity type Other Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00